IMGN has a product, good technology, cash, licensing deals and at least one very interesting wholly owned molecule 289. What they lack is strong management, leadership, strength in advanced drug development. SGEN could buy them cheap, IMGN shareholders would love to have SGEN stock and better management. I will take 1 for 2 right now. Let's get this deal done, combine forces and rule the ADC market!